Allow me to quote a few medical reviews of cannabinoids in medicine.
Cannabinoids are divided into phytocannabinoids,endogenous endocannabinoids, and synthetic cannabinoids. More than 60 phytocannabinoids have been identified within the cannabis plant. The primary phytocannabinoid respon- sible for cannabis’ psychoactive and physiological effects is delta9-tetrahydrocannabinol (THC).
THC is highly protein bound in the blood but the steady state volume of distribution is large (approximately 10 L/kg) due to its lipophilicity. THC’s half-life (t1/2) is variable based on the route of administration and dose but can be generally characterized by an initial t1/2 of 3–4 h, followed by a terminal t1/2 of 25–36 h with low levels of drug being eliminated over a longer period of time due to its large volume of distribution
This is why its dangerous to use with chemotherapy as it can displace the chemo in circulation.
Detectable levels of THC can be found in the urine for up to 12 days after use due to extensive enterohepatic recirculation of metabolites; however, this period could be longer for regular users
For those worried about urine tests, there you go
By contrast, cannabis smoke is carcinogenic in rodents and mutagenic in the Ames test. Cannabis smoke contains several of the same carcinogens as tobacco smoke at up to 50% higher concentrations and with three times the tar per cigarette. Respiratory mucosa exposed to chronic cannabis smoke shows pre-neoplastic histological and molecular changes
hospital-based case–control study, ever users of cannabis had a 2.6-fold (95% CI 1.1–6.6) increased risk of head and neck squamous cell carcinoma
heavy cannabis smokers in Northern Africa had an odds ratio of 2.62 (95% CI 1–6.86) for nasopharyngeal carcinomas
In experimental models of acute pain, inhaled cannabis resulted in dose-dependent pain relief whereas cannabis extracts had no effect
(remember smoking cannibis is carcinogenic and its only stronger than a placebo)
A subsequent randomized, double-blinded trial from Europe for patients with cancer-associated anorexia found no difference in weight gain or quality of life at 6 weeks for patients treated with cannabis extract (THC 2.5 mg daily and CBD 1 mg daily) or THC (2.5 mg daily) compared to patients given placebo
Patients given cannabinoids had increased side effects. The data for cannabinoids in cancer-associated anorexia based on these three randomized studies are weak and the data for inhaled cannabis for cancer-associated cachexia are lacking
taken from:
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–60.
Strasser F. Comparison of orally administered cannabis extract and Delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia–cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394–400.
Novotny M, Lee ML, Bartle KD. A possible chemical basis for the higher mutagenicity of marijuana smoke as compared to tobacco smoke. Experientia 1976;32:280–2
Moir D, Rickert WS, Levasseur G, et al. A comparison of main-stream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008;21:494–502
Singh R, Sandhu J, Kaur B, et al. Evaluation of the DNA dam-aging potential of cannabis cigarette smoke by the determination of acetaldehyde derived N2-ethyl-2 -deoxyguanosine adducts. ChemRes Toxicol 2009;22:1181–8.
Anyone who reads these articles and doesnt have basic physiology or pharmacology will see grand epic results for cannibis and its family. HOWEVER its only superior by 10 - 30 % against a placebo NOT its pharmaceutical rivals.
Sign up with Google
